Tags

Type your tag names separated by a space and hit enter

Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer.
Breast Cancer Res Treat. 2008 Mar; 108(1):35-41.BC

Abstract

In situ synthesis of estrogens is believed to be of great importance for the progression of breast cancer. In postmenopausal women most estrogens are synthesized in peripheral hormone-target tissues from circulating precursor steroids, by the enzymes involved in formation of active estrogens. One of the enzymes involved in this process is 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1. This enzyme catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17beta-HSD type 1 (HSD17B1) is located at 17q12-21. The aim of this study was to investigate altered gene copy number of HSD17B1 in breast cancer. We used real-time PCR and examined 387 postmenopausal breast tumors for amplification of HSD17B1, and if an increased mRNA level of this enzyme is associated with amplification of the gene. We also investigated whether amplification of HSD17B1 has a prognostic value. There was a significant correlation between gene copy number of HSD17B1 and mRNA expression level (P = 0.00002). ER-positive patients with amplification of HSD17B1 showed lower breast cancer survival than patients without amplification (P = 0.025). Among ER-negative patients there was no significant correlation between increased gene copy number of HSD17B1 and prognosis. Furthermore, we found that amplification of the gene had prognostic significance in multivariate analysis adjusting for other clinicopathological variables.

Authors+Show Affiliations

Department of Pathology/Cytology and Genetics, Division of Genetics, Linköping University Hospital, Linkoping, Sweden. cecilia.gunnarsson@lio.seNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17457667

Citation

Gunnarsson, Cecilia, et al. "Amplification of HSD17B1 Has Prognostic Significance in Postmenopausal Breast Cancer." Breast Cancer Research and Treatment, vol. 108, no. 1, 2008, pp. 35-41.
Gunnarsson C, Jerevall PL, Hammar K, et al. Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Res Treat. 2008;108(1):35-41.
Gunnarsson, C., Jerevall, P. L., Hammar, K., Olsson, B., Nordenskjöld, B., Jansson, A., & Stål, O. (2008). Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. Breast Cancer Research and Treatment, 108(1), 35-41.
Gunnarsson C, et al. Amplification of HSD17B1 Has Prognostic Significance in Postmenopausal Breast Cancer. Breast Cancer Res Treat. 2008;108(1):35-41. PubMed PMID: 17457667.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer. AU - Gunnarsson,Cecilia, AU - Jerevall,Piiha-Lotta, AU - Hammar,Karl, AU - Olsson,Birgit, AU - Nordenskjöld,Bo, AU - Jansson,Agneta, AU - Stål,Olle, Y1 - 2007/04/25/ PY - 2007/03/20/received PY - 2007/03/21/accepted PY - 2007/4/26/pubmed PY - 2008/5/21/medline PY - 2007/4/26/entrez SP - 35 EP - 41 JF - Breast cancer research and treatment JO - Breast Cancer Res Treat VL - 108 IS - 1 N2 - In situ synthesis of estrogens is believed to be of great importance for the progression of breast cancer. In postmenopausal women most estrogens are synthesized in peripheral hormone-target tissues from circulating precursor steroids, by the enzymes involved in formation of active estrogens. One of the enzymes involved in this process is 17beta-hydroxysteroid dehydrogenase (17beta-HSD) type 1. This enzyme catalyzes the interconversion of estrone (E1) to the biologically more potent estradiol (E2). The gene coding for 17beta-HSD type 1 (HSD17B1) is located at 17q12-21. The aim of this study was to investigate altered gene copy number of HSD17B1 in breast cancer. We used real-time PCR and examined 387 postmenopausal breast tumors for amplification of HSD17B1, and if an increased mRNA level of this enzyme is associated with amplification of the gene. We also investigated whether amplification of HSD17B1 has a prognostic value. There was a significant correlation between gene copy number of HSD17B1 and mRNA expression level (P = 0.00002). ER-positive patients with amplification of HSD17B1 showed lower breast cancer survival than patients without amplification (P = 0.025). Among ER-negative patients there was no significant correlation between increased gene copy number of HSD17B1 and prognosis. Furthermore, we found that amplification of the gene had prognostic significance in multivariate analysis adjusting for other clinicopathological variables. SN - 0167-6806 UR - https://www.unboundmedicine.com/medline/citation/17457667/Amplification_of_HSD17B1_has_prognostic_significance_in_postmenopausal_breast_cancer_ L2 - https://doi.org/10.1007/s10549-007-9579-7 DB - PRIME DP - Unbound Medicine ER -